Policy | August 06, 2021
Govt augments PSEs and Bharat Biotech to ramp up Covaxin production
CDSCO to fast-track trials and approval for COVID19 vaccine
CDSCO to fast-track trials and approval for COVID19 vaccine
Apollo hospital-Hyderabad, Kainos Hospital-Rohtak and Apex Hospital Jaipur have deployed this solution
Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -
It is designed to tackle mental health issues
This deal makes Meddo, one of the largest health-tech players in India
The Phase III clinical trial for NONS is expected to be completed by Q4 2021.
The company has decided to transfer our rights in relation to the lodex and Ostocalcium brands to GlaxoSmithKline Asia Private Limited
Q1 FY22 consolidated revenue grew 6% to Rs. 1,808 crore from Rs. 1,712 crore in Q1 FY21. Q1 FY22 Net Profit was Rs. 84 crore (vs. Rs. 149 crore in Q1 FY21).
Growing R&D budgets of global pharmaceutical companies is the opportunity that Veeda and Bioneeds expect to capitalise on.
The shareholders have also ratified the Board’s approval to allot 10 lakhs warrants to the Promoter, Managing Director and CEO, Mark Saldanha at the said price of Rs. 74 per warrant
Subscribe To Our Newsletter & Stay Updated
